Department of Psychiatry, Research School of Behavioural and Cognitive Neurosciences (BCN), University Medical Center Groningen, University of Groningen, Postbus 30.001, 9700, RB, Groningen, the Netherlands.
Department of Care Ethics, University of Humanistic Studies, Utrecht, The Netherlands.
Psychopharmacology (Berl). 2023 Jul;240(7):1547-1560. doi: 10.1007/s00213-023-06388-6. Epub 2023 May 24.
BACKGROUND: Ketamine and its enantiomers are widely researched and increasingly used to treat mental disorders, especially treatment-resistant depression. The phenomenology of ketamine-induced experiences and their relation to its psychotherapeutic potential have not yet been systematically investigated. AIMS: To describe the phenomenology of patient experiences during oral esketamine treatment for treatment-resistant depression (TRD) and to explore the potential therapeutic relevance of these experiences. METHODS: In-depth interviews were conducted with 17 patients after a 6-week, twice-weekly 'off label' generic oral esketamine (0.5-3.0mg/kg) treatment program. Interviews explored participants' perspectives, expectations, and experiences with oral esketamine treatment. Audio interviews were transcribed and analyzed using an Interpretative Phenomenological Analysis (IPA) framework. RESULTS: The effects of ketamine were highly variable, and psychological distress was common in most patients. Key themes included (a) perceptual effects (auditory, visual, proprioceptive), (b) detachment (from body, self, emotions, and the world), (c) stillness and openness, (d) mystical-type effects (transcendence, relativeness, spirituality), and (e) fear and anxiety. Key themes related to post-session reports included (a) feeling hungover and fatigued, and (b) lifting the blanket: neutralizing mood effects. CONCLUSION: Patients reported several esketamine effects with psychotherapeutic potential, such as increased openness, detachment, an interruption of negativity, and mystical-type experiences. These experiences deserve to be explored further to enhance treatment outcomes in patients with TRD. Given the frequency and severity of the perceived distress, we identify a need for additional support in all stages of esketamine treatment.
背景:氯胺酮及其对映体被广泛研究,并越来越多地用于治疗精神障碍,尤其是治疗抵抗性抑郁症。氯胺酮引起的体验的现象学及其与心理治疗潜力的关系尚未得到系统研究。
目的:描述接受口服氯胺酮治疗治疗抵抗性抑郁症(TRD)的患者的体验现象学,并探讨这些体验的潜在治疗相关性。
方法:对 17 名接受为期 6 周、每两周一次的“标签外”通用口服氯胺酮(0.5-3.0mg/kg)治疗方案的患者进行深入访谈。访谈探讨了参与者对口服氯胺酮治疗的看法、期望和体验。使用解释性现象学分析(IPA)框架对音频访谈进行转录和分析。
结果:氯胺酮的效果高度可变,大多数患者都有心理困扰。主要主题包括(a)知觉效应(听觉、视觉、本体感觉),(b)分离(身体、自我、情绪和世界),(c)静止和开放,(d)神秘型效应(超越、相对性、灵性),和(e)恐惧和焦虑。与治疗后报告相关的主要主题包括(a)感觉宿醉和疲劳,和(b)掀起毯子:中和情绪效应。
结论:患者报告了几种具有心理治疗潜力的氯胺酮效应,例如增加开放性、分离性、中断负面性和神秘型体验。这些体验值得进一步探索,以提高 TRD 患者的治疗效果。鉴于感知到的痛苦的频率和严重程度,我们认为需要在氯胺酮治疗的所有阶段提供额外的支持。
Expert Rev Neurother. 2019-10
Int J Neuropsychopharmacol. 2020-7-29
Eur Neuropsychopharmacol. 2023-5
J Med Internet Res. 2024-7-1
Psychedelic Med (New Rochelle). 2023-12-1
Front Psychiatry. 2023-11-23
Psychopharmacology (Berl). 2022-11
J Affect Disord. 2022-10-15
Br J Psychiatry. 2022-8
J Pain Res. 2022-6-15
Front Psychol. 2022-3-25
Anesthesiology. 2022-5-1
Int J Neuropsychopharmacol. 2022-4-19